Bio-Techne (NASDAQ:TECH) Stock Unloaded Rep. April McClain Delaney

Representative April McClain Delaney (D-Maryland) recently sold shares of Bio-Techne Corp (NASDAQ:TECH). In a filing disclosed on February 02nd, the Representative disclosed that they had sold between $1,001 and $15,000 in Bio-Techne stock on January 28th.

Representative April McClain Delaney also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of PTC (NASDAQ:PTC) on 1/30/2026.
• Sold $1,001 – $15,000 in shares of Wabtec (NYSE:WAB) on 1/30/2026.
• Sold $1,001 – $15,000 in shares of Trimble (NASDAQ:TRMB) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of BJ’s Wholesale Club (NYSE:BJ) on 1/28/2026.
• Sold $1,001 – $15,000 in shares of Trimble (NASDAQ:TRMB) on 1/28/2026.
• Purchased $1,001 – $15,000 in shares of Labcorp (NYSE:LH) on 1/28/2026.
• Sold $1,001 – $15,000 in shares of PTC (NASDAQ:PTC) on 1/23/2026.
• Sold $1,001 – $15,000 in shares of Somnigroup International (NYSE:SGI) on 1/22/2026.
• Sold $1,001 – $15,000 in shares of Wabtec (NYSE:WAB) on 1/22/2026.
• Sold $1,001 – $15,000 in shares of Morningstar (NASDAQ:MORN) on 1/15/2026.

Bio-Techne Stock Down 1.0%

TECH stock opened at $64.63 on Wednesday. Bio-Techne Corp has a one year low of $46.01 and a one year high of $79.28. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.81 and a current ratio of 4.22. The firm’s fifty day moving average is $63.15 and its 200 day moving average is $59.14. The firm has a market cap of $10.07 billion, a PE ratio of 131.90, a P/E/G ratio of 4.50 and a beta of 1.48.

Bio-Techne (NASDAQ:TECH) last issued its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $0.42 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.42. Bio-Techne had a net margin of 6.41% and a return on equity of 13.59%. The business had revenue of $286.56 million during the quarter, compared to the consensus estimate of $292.02 million. During the same quarter in the prior year, the firm posted $0.42 earnings per share. The company’s revenue was down 1.0% compared to the same quarter last year. On average, research analysts forecast that Bio-Techne Corp will post 1.67 EPS for the current year.

Hedge Funds Weigh In On Bio-Techne

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Asset Management One Co. Ltd. lifted its stake in Bio-Techne by 2.7% in the 4th quarter. Asset Management One Co. Ltd. now owns 5,752 shares of the biotechnology company’s stock worth $341,000 after purchasing an additional 153 shares in the last quarter. Oak Thistle LLC increased its holdings in shares of Bio-Techne by 1.9% in the third quarter. Oak Thistle LLC now owns 9,314 shares of the biotechnology company’s stock valued at $518,000 after purchasing an additional 173 shares during the last quarter. Allworth Financial LP lifted its position in Bio-Techne by 28.4% during the third quarter. Allworth Financial LP now owns 786 shares of the biotechnology company’s stock worth $44,000 after buying an additional 174 shares in the last quarter. Oppenheimer & Co. Inc. boosted its stake in Bio-Techne by 3.5% during the fourth quarter. Oppenheimer & Co. Inc. now owns 5,351 shares of the biotechnology company’s stock worth $315,000 after buying an additional 181 shares during the last quarter. Finally, Angeles Wealth Management LLC grew its holdings in Bio-Techne by 3.4% in the 3rd quarter. Angeles Wealth Management LLC now owns 5,703 shares of the biotechnology company’s stock valued at $317,000 after buying an additional 189 shares in the last quarter. 98.95% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

TECH has been the subject of several research analyst reports. UBS Group upped their target price on Bio-Techne from $65.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Evercore ISI set a $62.00 price target on shares of Bio-Techne and gave the stock an “in-line” rating in a report on Monday, January 5th. Wells Fargo & Company increased their price objective on shares of Bio-Techne from $59.00 to $70.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Benchmark reiterated a “buy” rating on shares of Bio-Techne in a research report on Tuesday. Finally, TD Cowen restated a “buy” rating on shares of Bio-Techne in a research report on Tuesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $70.57.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

About Bio-Techne

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.